Search

Displaying all 4 results
DrugBest match

Canagliflozin

go.drugbank.com/drugs/DB08907
ApprovedInvestigational

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 ...

  1. Drug

    Metformin

    go.drugbank.com/drugs/DB00331
    ApprovedInvestigational

    Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabe...

    Mixtures: Vokanamet (Canagliflozin 150mg/ Metformin 500mg) Film-Coated Tablet, Vokanamet (Canagliflozin 150mg/ Metformin 850mg) Film-Coated TabletCategories: metformin and canagliflozin
  2. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin

  3. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors